Show simple item record

dc.contributor.authorColeman, N.
dc.contributor.authorWoolf, David K
dc.contributor.authorWelsh, L.
dc.contributor.authorMcDonald, F.
dc.contributor.authorMacMahon, S.
dc.contributor.authorYousaf, N.
dc.contributor.authorPopat, S.
dc.date.accessioned2020-11-16T07:49:05Z
dc.date.available2020-11-16T07:49:05Z
dc.date.issued2020en
dc.identifier.citationColeman N, Woolf D, Welsh L, McDonald F, MacMahon S, Yousaf N, et al. EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. J Thorac Oncol. 2020;15(10):e162-e5.en
dc.identifier.pmid32981603en
dc.identifier.doi10.1016/j.jtho.2020.05.006en
dc.identifier.urihttp://hdl.handle.net/10541/623363
dc.description.abstractNoneen
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jtho.2020.05.006en
dc.titleEGFR Exon 20 insertion (A763_Y764insFQEA) mutant NSCLC is not identified by Roche Cobas Version 2 tissue testing but has durable intracranial and extracranial response to osimertiniben
dc.typeArticleen
dc.contributor.departmentLung Unit, The Royal Marsden Hospital, Chelsea, London, United Kingdom; Institute of Cancer Research, Sutton, London,en
dc.identifier.journalJournal of Thoracic Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record